Blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities
Authors Okazaki K, Makinodan M, Yamamuro K, Takata T, Kishimoto T
Received 22 August 2016
Accepted for publication 8 November 2016
Published 14 December 2016 Volume 2016:12 Pages 3195—3198
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Taro Kishi
Kosuke Okazaki, Manabu Makinodan, Kazuhiko Yamamuro, Tomoyo Takata, Toshifumi Kishimoto
Department of Psychiatry, Nara Medical University School of Medicine, Kashihara, Japan
Objective: Methamphetamine (MA) use has recently been associated with high levels of psychiatric hospitalization and serious social dysfunction. MA use causes frequent psychotic symptoms, which can be treated with antipsychotics. However, people with intellectual disabilities (ID) are vulnerable to adverse effects resulting from treatment with antipsychotic medications.
Method: We report two cases of MA-induced psychosis (MAP) in patients with ID who were treated with the antipsychotic blonanserin.
Results: In both the cases presented, symptoms of psychosis were improved by switching medications from other antipsychotic drugs to blonanserin. Despite the presence of ID in these patients, no significant adverse effects, such as sedation, were detected after treatment with blonanserin.
Conclusion: Blonanserin may be an effective and well-tolerated pharmacotherapeutical treatment for patients with MAP comorbid with ID. However, further work is necessary to validate this claim.
Keywords: methamphetamine, methamphetamine-induced psychosis, intellectual disabilities, blonanserin
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]